Quick Takeaways
- Avoro Capital Advisors LLC filed SCHEDULE 13G/A for Arrowhead Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (ARWR).
- Disclosed ownership: 9.6%.
- Date of event: 31 Dec 2024.
Avoro Capital Advisors LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Arrowhead Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (ARWR)
- Filing Manager
- Avoro Capital Advisors LLC
- Reporting Manager
- Avoro Capital Advisors LLC
- Symbol
- ARWR
- Shares outstanding
- 125,297,417 shares
- Disclosed Ownership
- 12,028,552 shares
- Ownership
- 9.6%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Feb 2025, 09:31:24 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Avoro Capital Advisors LLC disclosed 9.6% ownership in Arrowhead Pharmaceuticals, Inc. Common Stock, par value $0.001 per share (ARWR) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 09:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.6% | 12,028,552 | 12,028,552 | 0 | /s/ Scott Epstein | Scott Epstein, Chief Financial Officer & Chief Compliance Officer | |
| Behzad Aghazadeh | 9.6% | 12,028,552 | 12,028,552 | 0 | /s/ Behzad Aghazadeh | Behzad Aghazadeh, Individually |